# Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)

> **NCT04463264** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Laboratorios Roemmers S.A.I.C.F.** · enrollment: 135 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04463264
- **Lead sponsor:** Laboratorios Roemmers S.A.I.C.F.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-26
- **Primary completion:** 2020-11-15
- **Final completion:** 2020-12-26
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04463264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04463264, "Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04463264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*